GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback